Our Compound
MetalloBio is developing two novel ruthenium-based antimicrobial compounds that will be used to treat multi-drug resistant pathogens. Currently, both compounds are in preclinical development, with the aim of reaching phase I (first in man) clinical trials by 2025.
RuTMP
A broad spectrum antimicrobial with activity against Gram-positive and Gram-negative bacteria including vancomycin resistant Enterococcus and carbapenem resistant strains of Enterobacteriacae, Pseudomonas and Acinetobacter. RuTMP is non-toxic and has shown strong efficacy both in-vitro and in-vivo. The final stages of pre-clinical candidate evaluation are in progress.
RuRuTMP
More active than clinically available antibiotics, with activity retained against multi-drug resistant, Gram-negative bacteria, including carbapenem resistant strains of Enterobacteriacae, Pseudomonas and Acinetobacter, RuRuTMP has a multi-modal mechanism of action and shows strong efficacy both in-vitro and in-vivo. The final stages of pre-clinical candidate evaluation are in progress.